Insider Selling: ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells 10,796 Shares of Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Jaume Pons sold 10,796 shares of the company’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $1.58, for a total value of $17,057.68. Following the transaction, the insider now directly owns 580,714 shares in the company, valued at approximately $917,528.12. The trade was a 1.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

ALX Oncology Price Performance

NASDAQ ALXO opened at $1.81 on Friday. The company has a 50-day moving average price of $1.53 and a two-hundred day moving average price of $2.82. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The stock has a market cap of $95.46 million, a price-to-earnings ratio of -0.61 and a beta of 1.04. ALX Oncology Holdings Inc. has a 52 week low of $1.19 and a 52 week high of $17.83.

Institutional Investors Weigh In On ALX Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of ALXO. Point72 Asset Management L.P. bought a new stake in shares of ALX Oncology during the 2nd quarter worth about $1,834,000. GSA Capital Partners LLP bought a new stake in ALX Oncology during the third quarter worth approximately $88,000. Marshall Wace LLP lifted its position in ALX Oncology by 423.0% in the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after purchasing an additional 514,133 shares during the period. SG Americas Securities LLC boosted its stake in ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after purchasing an additional 6,888 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of ALX Oncology by 394.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after purchasing an additional 5,200 shares during the period. 97.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ALXO shares. Jefferies Financial Group cut ALX Oncology from a “buy” rating to a “hold” rating and lowered their price target for the stock from $12.00 to $2.00 in a report on Thursday, December 19th. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of ALX Oncology in a report on Wednesday, December 18th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research report on Wednesday, December 18th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, ALX Oncology currently has an average rating of “Moderate Buy” and an average price target of $8.50.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.